MRNS - Marinus Pharmaceuticals, Inc.
4.52 -0.01 (-0.17%)
After hours: 4:11PM EDT
| Previous Close | 4.70 |
| Open | 4.70 |
| Bid | 4.12 x 1000 |
| Ask | 4.70 x 2000 |
| Day's Range | 4.39 - 4.70 |
| 52 Week Range | 1.13 - 9.87 |
| Volume | 408,622 |
| Avg. Volume | 1,105,043 |
| Market Cap | 183.559M |
| Beta | 3.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | Apr 30, 2018 - May 4, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.00 |
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
RADNOR, Pa., March 08, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today ...
- Investor's Business Daily•2 months ago
Biotech Jumps After Rival Pushes Back Depression Drug Tests
Sage jumped Tuesday after rival Marinus said it would delay top-line results of a Phase 2 study in postpartum depression.
- Motley Fool•2 months ago
Here's Why Marinus Pharmaceuticals Dropped as Much as 17.7% Today
The biopharma's slide continues -- for good reason this time.
- MarketWatch•2 months ago
Marinus Pharma shares slide 14% premarket after company posts wider-than-expected loss
Shares of biotech Marinus Pharmaceuticals Inc. slid more than 14% in premarket trade Tuesday, after the company reported a wider-than-expected loss for 2017. The company, which is focused on developing ...
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
RADNOR, Pa., March 06, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today ...
- Simply Wall St.•2 months ago
Is There Now An Opportunity In Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
Marinus Pharmaceuticals Inc (NASDAQ:MRNS), a pharmaceuticals company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab — Future Expectations, Projections Moving into 2018
NEW YORK, Feb. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Discovery ...
- GlobeNewswire•2 months ago
Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
RADNOR, Pa., Feb. 07, 2018-- Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced ...
- Motley Fool•4 months ago
3 Best Healthcare Stocks of 2017
The key to big gains last year? Start off small.
- Market Realist•4 months ago
Key Risks Facing Marinus Pharmaceuticals in December 2017
Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.
- Market Realist•4 months ago
How Do Marinus Pharmaceuticals’ Financials Look?
Marinus Pharmaceuticals (MRNS) raised $37.7 million in net proceeds from a secondary public offering of common stock.
- Market Realist•4 months ago
Ganaxalone Faces Stiff Competition from Other Drugs under Development
Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected ...
- Market Realist•4 months ago
Why Ganaxalone Is a Promising Drug Candidate
Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017....
- Market Realist•4 months ago
What Analysts Recommend for Marinus Pharmaceuticals in December
Both of the analysts covering Marinus Pharmaceuticals in December 2017 have given the company a “buy” rating.
- Motley Fool•4 months ago
Why Mattel, Marinus Pharmaceuticals, and Northern Dynasty Minerals Slumped Today
Learn why these stocks fell in a strong market.
- Motley Fool•4 months ago
The 3 Best Biotech Stocks of 2017
What did it take to rank among the top three biotech stocks this year? At least a 440% gain.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Trending Tickers: ImmunoCellular Therapeutics and Marinus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...
- Motley Fool•4 months ago
Here's Why Marinus Pharmaceuticals Is Soaring Today
The tiny yet promising biopharma may be taken more seriously after today.
- Benzinga•5 months ago
Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News
Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) closed up 39.6 percent Thursday and continued another 3.9 percent pre-market Friday — but not on its own merits. The stock moved mostly on sympathy for SAGE ...
- Motley Fool•5 months ago
Here's Why Marinus Pharmaceuticals Rose as Much as 41.1% Thursday
Investors are hoping a competitor's drug will pave the way for the company's own drug.
- ACCESSWIRE•5 months ago
Today’s Research Reports on Stocks to Watch: Marinus Pharmaceuticals, Inc. and Otonomy, Inc.
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Shares of Marinus Pharmaceuticals closed up 14% higher on Thursday after SAGE Therapeutics revealed positive clinical trial data for a postpartum depression ...
- Motley Fool•5 months ago
2 Antidepressant-Focused Biotech Stocks Are Surging Today. Here's Why.
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
